GlassScriptPhysician profile
Scott Fink
NPI 1023060480
$237,500.01
in general payments reported to CMS, 2019-2025
39 companies · $36K in 2025
The $36K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $23K · 2021: $16K · 2022: $35K · 2023: $30K · 2024: $57K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $69K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $14K · Travel and Lodging: $12K · Consulting Fee: $11K · Food and Beverage: $11K · Honoraria: $6,428.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $68,822.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $13,500.00 |
| Travel and Lodging | $11,635.26 |
| Consulting Fee | $11,387.50 |
| Food and Beverage | $10,638.79 |
| Honoraria | $6,427.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $129,578.05 | 2019-2025 | Epclusa, Livdelzi |
| Abbvie INC. | $38,313.16 | 2019-2025 | |
| Madrigal Pharmaceuticals | $31,725.73 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $23,425.44 | 2019-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $6,993.44 | 2024-2025 | Iqirvo |
| Mallinckrodt Hospital Products INC. | $2,167.55 | 2020-2025 | Terlivaz |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,109.38 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $442.14 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $414.81 | 2020-2025 | Tremfya, Stelara, Simponi |
| Pfizer INC. | $295.19 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $258.26 | 2022-2025 | Dupixent |
| Novo Nordisk INC | $251.30 | 2025 | Wegovy |
| Genzyme Corporation | $234.06 | 2022-2025 | |
| Qol Medical, LLC | $131.10 | 2019-2024 | Sucraid, Sucraid |
| Lilly USA, LLC | $122.71 | 2024-2025 | Omvoh |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $116.45 | 2019 | |
| Ardelyx, INC. | $107.31 | 2024-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $88.42 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $85.18 | 2022-2025 | Injectafer |
| Celgene Corporation | $79.87 | 2021-2023 | Zeposia |
| Dova Pharmaceuticals | $69.86 | 2019 | |
| Shionogi INC | $57.85 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.43 | 2023-2024 | Cyltezo |
| Alexion Pharmaceuticals, INC. | $50.64 | 2019 | |
| Octapharma USA, INC. | $47.63 | 2019 | |
| Redhill Biopharma INC. | $31.93 | 2022 | |
| Boston Scientific Corporation | $29.22 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $25.98 | 2019-2024 | Rebyota |
| Pharmacosmos Therapeutics INC. | $25.48 | 2022 | |
| Organon LLC | $24.94 | 2024 | |
| Ucb, INC. | $22.18 | 2019 | |
| Fresenius Kabi USA, LLC | $21.89 | 2023 | Idacio |
| Allergan, INC. | $21.69 | 2019 | |
| Alfasigma USA, INC. | $19.04 | 2020 | |
| Ironwood Pharmaceuticals, INC | $18.93 | 2020 | |
| Nestle Healthcare Nutrition INC. | $13.43 | 2021 | |
| W. L. Gore & Associates, INC. | $12.85 | 2020 | |
| Intra-Sana Laboratories | $10.49 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Fink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.